PUBLICATION OF CIRCULAR AND NOTICE OF GM
07/12/2023 18:04
For best results when printing this announcement, please click on link below: http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231207:nRSG0978Wa&default-theme=true RNS Number : 0978W BioPharma Credit PLC 07 December 2023 7 DECember 2023 BIOPHARMA CREDIT PLC (THE "COMPANY") Publication of Circular and Notice of General Meeting Further to the announcement on 1 November 2023, the Company today announces that it has published a shareholder circular (the "Circular") and notice of general meeting (the "General Meeting") for the purpose of proposing a vote in relation to the continuation of the Company (the "Proposals"). The detailed reasons for and background to the Proposals are set out in the Circular. The Board unanimously recommends that Shareholders vote in favour of the Continuation Resolution. The Continuation Resolution must be passed by a majority of at least half of the votes of the Shareholders entitled to vote and voting, whether in person or by proxy, at the General Meeting. If the Continuation Resolution is passed by Shareholders at the General Meeting, the Directors will be required to put a further continuation resolution to Shareholders no later than the Company's annual general meeting in 2025, in accordance with Article 152(1). If the Continuation Resolution is not passed by Shareholders at the General Meeting, then, under the Articles, the Directors shall be required, within six months of the resolution not being passed, to put proposals to the Shareholders for the reconstruction, reorganisation or winding up of the Company. The General Meeting will be held at the offices of Herbert Smith Freehills LLP, Exchange House, Primrose Street, London EC2A 2EG at 10 a.m. on 28 December 2023. The Circular will be posted to Shareholders today and a copy of the Circular can be found on the Company's website at http://www.bpcruk.com. A copy of the Circular has also been submitted to the National Storage Mechanism and will shortly be available for viewing online at https://data.fca.org.uk/#/nsm/nationalstoragemechanism (https://data.fca.org.uk/#/nsm/nationalstoragemechanism) . Terms used in this announcement unless otherwise defined, shall have the same meaning as set out in the Circular. Enquiries: BioPharma Credit plc via Link Company Matters Limited Company Secretary +44 (0) 333 300 1950 Buchanan David Rydell / Mark Court / Jamie Hooper / Henry Wilson +44 (0)20 7466 5000 biopharmacredit@buchanan.uk.com Notes to Editors: BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products. LEI: 213800AV55PYXAS7SY24 This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com (mailto:rns@lseg.com) or visit www.rns.com (http://www.rns.com/) . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy) . END NOGTRBPTMTMMBMJ